Sinonasal teratocarcinosarcoma (SNTCS) is a rare malignancy characterized by a highly aggressive nature. Itmainly arises in the ethmoidal ormaxillary sinus. SNTCShas a poor prognosis, with a mean survival rate of 55% at 2 years. Herein, we presented a case of advanced SNTCS successfully treated with surgery followed by chemoradiotherapy plus targeted therapy and reviewed the published literature on this rare entity.
| [1] |
Peralta SuarezG, DibsK, CarrauRL, Schoenfield L, BlakajDM, TinocoG. Sinonasal teratocarcinosarcoma: a therapeutic dilemma. BMJ Case Rep. 2022;15(11):e252429.
|
| [2] |
ChapurinN, TottenDJ, MorseJC, et al. Treatment of sinonasal teratocarcinosarcoma: a systematic review and survival analysis. Am J Rhinol Allergy. 2021;35(1):132-141.
|
| [3] |
Krishna KumarK, Sundararajan I, RangachariV, SumathiV. Sinonasal teratocarcinosarcoma-A case report. Indian J Otolaryngol Head Neck Surg. 2007;59(2):148-150.
|
| [4] |
QuYC, FULY, ZengDH, et al. Teratocarcinoma sarcoma of nasal cavity and paranasal sinuses: a case report. Chin J CT and MRI. 2015;13(9):118-120.
|
| [5] |
ShiYY, ZhangY, ChengJL, et al. A case of paranasal sinus teratocarcinoma sarcoma involving the left frontal lobe. Chin J Interv Imaging Ther. 2018;15(7):451.
|
| [6] |
MisraP, HusainQ, SviderPF, et al. Management of sinonasal teratocarcinosarcoma: a systematic review. Am J Otolaryngol. 2014;35(1):5-11.
|
| [7] |
HeffnerDK, HyamsVJ. Teratocarcinosarcoma (malignant teratoma?) of the nasal cavity and paranasal sinuses: A clinicopathologic study of 20 cases. Cancer. 1984;53(10):2140-2154.
|
| [8] |
WangY, SunXJ, et al. Imaging analysis and literature review of sinonasal teratocarcinosarcoma:report of one case. J Chin Clin Med Imag. 2022;33(3):221-223.
|
| [9] |
WangSY, LiSM, et al. Pathological features and diagnosis of teratocarcinoma sarcoma in nasal cavity and paranasal sinuses. Chin J Pathol. 2007;36(8):534-538.
|
| [10] |
SableM, KakkarA, GargK, et al. Sinonasal teratocarcinosarcoma: an underdiagnosed entity posing diagnostic challenges. Turk Neurosurg. 2017;27(3):468-471.
|
| [11] |
BirkelandAC, BurginSJ, YanikM, et al. Pathogenetic analysis of sinonasal teratocarcinosarcomas reveal actionable β-catenin overexpression and a β-catenin mutation. J Neurol Surg B Skull Base. 2017;78(4):346-352.
|
| [12] |
RooperLM, UddinN, GaganJ, et al. Recurrent loss of SMARCA4 in sinonasal teratocarcinosarcoma. Am J Surg Pathol. 2020;44(10):1331-1339.
|
| [13] |
ShenG, ZhengF, RenD, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120.
|
| [14] |
LeeNY, Terezakis SA. Intensity-modulated radiation therapy. J Surg Oncol. 2008;97(8):691-696.
|
RIGHTS & PERMISSIONS
2024 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.
PDF
